[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
June 7, 1985

The Lipid Research Clinics Coronary Primary Prevention Trial-Reply

JAMA. 1985;253(21):3091. doi:10.1001/jama.1985.03350450063009

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


In Reply.—  The analysis of the LRC-CPPT results was entirely consistent with the hypothesis set forth in the study protocol adopted by the LRC investigators in 1973: "It is postulated that cholesterol reduction with a bile acid sequestrant will produce a significant decrease in the death rate from atherosclerotic coronary heart disease and in the occurrence rate of definite nonfatal myocardial infarction in a group of asymptomatic patients with primary type II hyperlipoproteinemia, also receiving a cholesterol lowering diet, when compared with a diet and placebo treated group." The term "significant" was not defined in terms of a particular statistical probability level.The statement cited by Drs L'Abbeé, Detsky, and Logan was taken from a published description of the procedure for estimating a sample size sufficient to provide the LRC-CPPT with the statistical power to test this hypothesis. The intent of this statement was to explain to the reader the